• Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy

Browse Tag

cancer research

The AMG 510 model binding the KRAS which is mutant. Binding is irreversible, hindrance constant is viable (nanomolar) in pharmacodynamics terms. Be that as it may, it's effectiveness should be demonstrated clinically. One day this synthetic compound may hit the market and become popular among cancer patients.
March 8, 2021
Pharma Interest

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against standard non-small cell lung cancer, NSCLC, yet in addition against the KRAS-mutant malignancy which seems, by all accounts, aggressive, barely accessible by chemotherapy and

More
July 30, 2020

Made-in-Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials

First dose of ETC-159 administered in Phase 1B of clinical trials, advancing

November 27, 2019

Generic Oncology Drugs Market Holds Promising Opportunities for Small Molecule Modalities

Anticipated to surpass the US$ 20 Billion mark in 2019, generic oncology

The AMG 510 model binding the KRAS which is mutant. Binding is irreversible, hindrance constant is viable (nanomolar) in pharmacodynamics terms. Be that as it may, it's effectiveness should be demonstrated clinically. One day this synthetic compound may hit the market and become popular among cancer patients.
Pharma Interest

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

March 8, 2021

Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against

More
Pharmaceutical Articles

Made-in-Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials

July 30, 2020

First dose of ETC-159 administered in Phase 1B of clinical trials, advancing the development of this drug to treat solid

More
Pharma Interest

Generic Oncology Drugs Market Holds Promising Opportunities for Small Molecule Modalities

November 27, 2019

Anticipated to surpass the US$ 20 Billion mark in 2019, generic oncology drugs will witness an increased demand in the

More
Pharma Interest

How Medical Research Can Tackle the Deadly Legacy of Asbestos

July 9, 2018

Post world war two, the UK had the difficult task ahead of rebuilding cities decimated during the blitz. Asbestos was

More
Pharmaceutical News

Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway

April 18, 2018

NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer,

More
  • Can You Sue Your Doctor for Blindness Caused by Elmiron®?
  • Experts advise European SME packaging firms to expand or seek acquisition prior to Pharmapack Europe
  • FIP advances sustainable health systems by providing new guidance for self-managing reflux symptoms
  • APAC overview: trends, challenges, and possibilities for growth in the MarTech sector
  • Modernizing Therapeutic Cell Production

© 2010-2022 PharmaMirror.com - All Rights Reserved.

  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy
Go toTop